Shandong Boan Biotechnology Co., Ltd. (HKG:6955)

Hong Kong · Delayed Price · Currency is HKD

4.310

+0.010 (0.23%)

Aug 21, 2026, 4:08 PM HKT

-71.30% (1Y)

Market Cap	2.68B -71.3%
Revenue (ttm)	873.36M +8.1%
Net Income	7.95M -90.2%
EPS	0.01 -90.9%
Shares Out	622.33M
PE Ratio	337.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,724,600
Open	4.300
Previous Close	4.300
Day's Range	4.175 - 4.365
52-Week Range	4.110 - 16.520
Beta	0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About HKG:6955

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of post... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 696

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 6955

Full Company Profile

Financial Performance

In 2025, HKG:6955's revenue was 784.82 million, an increase of 8.06% compared to the previous year's 726.32 million. Earnings were 7.14 million, a decrease of -90.24%.

Financial numbers in CNY Financial Statements